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Introduction: Mavoglurant is a noncompetitive antagonist at the 
metabotropic glutamate receptor 5 (mGluR5) currently being inves-
tigated as oral treatment of Parkinson’s disease–associated levodopa-
induced dyskinesia (PD-LID) and fragile X syndrome (FXS). This 
study evaluated the impact of single therapeutic and supratherapeutic 
intravenous (IV) doses of mavoglurant on the QTc interval duration 
in healthy subjects in compliance with the ICH E14 guideline.
Patients (or Materials) and Methods: In a pilot-phase, the safety 
and tolerability of single, ascending IV doses of 25 mg, 37.5 mg, 
and 50 mg of mavoglurant was assessed in 36 healthy subjects (n = 
12 per dose level). Subsequently, a randomized, placebo- and active-
controlled, 4-period, single-center, crossover thorough QTc study has 
been conducted in 76 healthy subjects with the following single-dose 
treatments: therapeutic and supratherapeutic dose of mavoglurant, 
400-mg moxifloxacin, and placebo. Mavoglurant was administered 
intravenously in a double-blind fashion, while the positive control 
moxifloxacin was orally administered in an open-label fashion. 
Holter ECG monitoring was performed up to 24 hours postdosing, 
and QTc data were derived from triplicate ECGs extracted at 3 pre-
dose (= baseline) and 12 postdose time points.
Results: An acceptable safety and tolerability of mavoglurant was 
confirmed at single IV doses of 25 mg, 37.5 mg, and 50 mg according 
to predefined criteria. Hence, doses of 25-mg and 50-mg mavoglurant 
were selected as therapeutic and supra-therapeutic dose for the core 
TQT study. The upper bound of the 90% 2-sided CI of the placebo 
and baseline-corrected QTcF (= Δ Δ QTcF) did not exceed 10 ms at 
any postdose time point for both doses of 25-mg and 50-mg mavo-
glurant. The maximum QTcF prolongation of 1.98 ms (90% CI, 
0.58–3.38) on 25 mg and 1.49 ms (90% CI, 0.10–2.88) on 50 mg 
were observed 3 hours’ postdosing. The PK/PD analysis confirmed 
the lack of an association between AFQ056 plasma concentrations 
and Δ Δ QTcF data over the entire range of Cmax data at 25-mg and 
50-mg mavoglurant (r2 < 0.01). An outlier analysis showed no sub-
jects with newly identified QTcF intervals > 480 ms or any QTcF pro-
longation > 60 ms compared with baseline in any treatment group. 
Study validity was confirmed given that the lower bound of the 90% 
CI of Δ Δ QTcF for moxifloxacin was > 5 ms at 4 predefined postdose 
time points (1, 2, 3, and 4 hours) (Bonferroni-adjusted P < 0.0125).
Conclusion: In this thorough QTc study, the lack of any clinically 
relevant QTc prolongation was demonstrated for both therapeutic 
and supratherapeutic single IV doses of 25-mg and 50-mg mavo-
glurant.
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Introduction: In this study, an in vitro bioassay of 1,5-dimethyl 
citrate monohydrate was carried out; 1,5-dimethyl citrate mono-
hydrate is a hydrated citric acid derivative with molecular formula 
C8H12O7·H2O isolated from Mangifera indica fruit
Patients (or Materials) and Methods: To support the hypothesis that 
the compound may have effect on smooth muscles, the activity of this 
pure compound on the longitudinal smooth muscles of isolated guinea 
pig ileum, rabbit jejunum, and guinea pig trachea was determined.
Results: Graded doses of the compound (0.5 mg/mL and 1 mg/
mL) showed a dose-dependent increase in contraction of the lon-
gitudinal smooth muscle of the isolated guinea pig ileum similar to 
histamine, and this contraction was antagonized by mepyramine. 
The compound was thus speculated to be a histaminergic agonist, 
which acts on the H1 histamine receptors found on smooth muscles. 
Activation of these H1 receptors in smooth muscle cells causes an 
increase in phosphoinositol hydrolysis and increase in intracellular 
calcium which brings about contraction of intestinal smooth muscle. 
The compound, however, at a concentration of 1 mg/mL produced 
no remarkable effect on the rabbit jejunum. Because the compound 
did not produce any remarkable effect on the rabbit jejunum, it is 
possible to speculate that the compound 1,5-dimethyl citrate mono-
hydrate at 1 mg/mL does not activate the cell specific receptors on 
the smooth muscles neither does it interact with voltage-operated 
Ca2+ channel. The compound also at a concentration of 5 mg/mL 
produced no appreciable response on guinea pig trachea.
Conclusion: This suggests that the compound may not interact with 
the receptors present to cause any remarkable response.
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Introduction: Melitor®/agomelatine/ is an melatonergic antidepres-
sant developed by the pharmaceutical company Servier. It is marketed 
for the treatment of major depressive disorder and has been reported 
to have a reduced level of sexual side effects as well as discontinuation 
effects compared with some other antidepressants. Agomelatine may 
also have positive effects on sleep.
Patients (or Materials) and Methods: According to Serbian Law 
on Medicinal Products and Medical Devices, regulatory procedural 
steps taken for getting Marketing Authorisation Approval in Serbia, 
started on 2011 year. Assesment of submitted documentation/Module 
1-5 Common Technical Document/ lasted longer, because of waiting 
additional regulatory data requested from the manufacturer.
Results: After evaluation submitted documentation by ALIMS’s 
Assessors, and re-evaluation the same documentation by the 
experts that are in Advising Working Group for medicinal products 
of Medicines and Medical Devices Agency of Serbia , the ALIMS 
requested again additional data related to efficacy and safety of this 
drug. The explanation of this action was: Mechanism of action of 
agomelatin does not support the pharmacotherapeutic principles of 
threating major depression.
Results of submitted clinical trials did not prove the efficacy of 
this drug. After oral administration, pharmacokinetic results showed 
nonlinearity in wide dose range and rough proportionality inside 
the therapeutic dose range. As postmarketing follow-up reports, 
applicant for getting Marketing Authorization Approval submitted 
4 Periodic Update Repotrs / PSURs/. On the basis of these PSURs, it 
could not be concluded that benefit/ risk assessment of agomelatin 
in the treatment of major depression is positive.
Conclusion: After several meetings, relevant ALIMS’ experts sug-
gested refusal of Melitor® registration. The regulatory story is still 
lasting, because applicant lodged the complaint on ALIMS’ decision 
